Research Applications for Striatech Products

Autoimmune Demyelinating Diseases: Cross-Entity Mechanisms and Visual-System Endpoints in Preclinical Models

Multiple sclerosis, NMOSD, MOGAD, and their experimental analogues — distinct immunopathologies that converge on shared cascades of complement activation, microglial myelin stripping, and secondary axon degeneration.
Introduction

What Are Autoimmune Demyelinating Diseases?

Autoimmune demyelinating diseases are a family of CNS conditions in which adaptive and innate immune mechanisms converge on myelin, oligodendrocytes, and the axons they insulate, producing recurrent or progressive white matter injury. The group encompasses multiple sclerosis (MS) in its relapsing-remitting and progressive forms, neuromyelitis optica spectrum disorder (NMOSD), MOG antibody-associated disorder (MOGAD), acute disseminated encephalomyelitis (ADEM), and a spectrum of experimental models including the classical MOG35-55 EAE, MP4 EAE, B cell-dependent EAE, passive-transfer NMOSD, and the Theiler murine encephalomyelitis virus (TMEV) model. Despite their individual immunopathological signatures – T cell-dominant in MS, astrocyte-targeting aquaporin-4 antibodies in NMOSD, MOG-specific IgG in MOGAD – these entities share common downstream effector cascades: complement activation, microglial and macrophage-mediated myelin stripping, secondary axon degeneration, and oligodendrocyte loss.

This page focuses specifically on the shared and divergent mechanisms across autoimmune demyelinating entities and their common visual-system translational endpoints, sitting above the narrower disease-specific pages for individual conditions.

This topic spans multiple application areas, including: Neuroinflammation and Autoimmune CNS Disease, Ocular Inflammation and Immune-Mediated Eye Disease, Rare and Inherited CNS and Eye Disorders (such as Pelizaeus-Merzbacher disease), Systemic Aging and CNS Decline, Optic Neuritis,, Optic Nerve Damage and Axon Degeneration

Vision: A Window into the brain 

Why Vision? The Optic Nerve as the Shared Sentinel Endpoint for Autoimmune Demyelinating Research

If you work on MS, NMOSD, or MOGAD and do not primarily study the eye, the visual system is still a strategically important endpoint for your preclinical work. The optic nerve is a tract of CNS white matter that is anatomically isolated, optically accessible, and functionally quantifiable. All three major autoimmune demyelinating entities preferentially attack the optic nerve – MS produces optic neuritis in up to 50 percent of patients, NMOSD optic neuritis is typically more severe and bilateral, and MOGAD produces optic neuritis as its most common clinical feature. This convergence is not coincidental: the optic nerve shares the myeloarchitecture and immune access routes of spinal and brain white matter, but adds the practical advantage that its function can be read out non-invasively and repeatedly via optomotor acuity (OptoDrum), pattern ERG, VEP, and OCT-RNFL in the same living animal.

For spinal cord or brain-focused MS researchers, this means optic nerve function provides a complementary, quantifiable, non-invasive window on the demyelinating process that does not require terminal endpoints at each time point. OptoDrum in particular measures the subcortical optomotor reflex – a retina-to-brainstem pathway – in awake, freely moving rodents without anaesthesia, enabling repeated longitudinal sampling across relapse and remission cycles, drug washout periods, and aging time courses that would be impractical with invasive endpoints alone.

Animal Models

Common Animal Models for Autoimmune Demyelinating Disease Research

  • MOG35-55 EAE (T cell-driven, relapsing or monophasic): The most widely used MS model. Active immunisation with MOG35-55 peptide in C57BL/6 mice elicits a CD4+ T cell-dominated CNS autoimmune attack. Optic neuritis is a consistent feature; OptoDrum has quantified visual acuity loss and recovery across relapse-remission cycles in this model.
  • MP4 EAE (chronic progressive; T cell + B cell): Immunisation with MBP-PLP4 fusion protein produces a chronic progressive demyelinating course that better models the progressive MS phenotype. Visual pathway involvement is documented with OptoDrum-based longitudinal tracking.
  • B cell-dependent EAE (humoral component; MOG antibody-positive): A variant model in which B cell responses and MOG-specific antibodies drive demyelination alongside T cell-mediated inflammation, bridging the classical EAE paradigm to MOGAD immunopathology. OptoDrum documents functional visual consequences of the humoral immune attack. (Joly et al., 2022, J Neuroinflammation.)
  • NMOSD passive-transfer model (AQP4-IgG): Passive transfer of aquaporin-4-specific antibodies recapitulates the astrocyte-targeted pathology of NMOSD, including severe optic nerve inflammation. OptoDrum has characterised the functional visual profile of AQP4-antibody-mediated attack, distinguishing it from classical EAE. (Remlinger et al., 2023, Neurol Neuroimmunol Neuroinflamm.)
  • CX3CR1 microglial model (aging-demyelination interaction): A model combining aging and autoimmune inflammation in which microglial CX3CR1 signalling drives optic nerve demyelination. OptoDrum documents functional visual consequences longitudinally, making this model uniquely suited to studying the age-accelerated demyelination axis. (Groh et al., 2025, Nat Neurosci.)
  • PLP-deficient model (Pelizaeus-Merzbacher disease; rare inherited demyelination): PLP1 mutations cause Pelizaeus-Merzbacher disease, an X-linked leukodystrophy. This model provides evidence that microglial demyelination context determines functional outcome even in non-autoimmune demyelinating disease, with OptoDrum tracking visual acuity as a functional correlate of myelination across disease stages. (Groh et al., 2023, Nat Commun.)
Research Questions

How Can Striatech Tools support Your Study?

Select a question that matches your research objective to see which instruments are relevant, what challenge they address, and what the published evidence shows.
01
How Do MS, NMOSD, and MOGAD Differ in Their Immune Mechanisms and Visual Phenotypes, and Which Preclinical Models Best Capture Each?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

MS, NMOSD, and MOGAD engage distinct immune effectors – CD4+ T cells and intermittent B cell activity in MS, AQP4-targeting IgG and complement in NMOSD, MOG-specific IgG in MOGAD – and produce distinguishable optic nerve and visual functional profiles. OptoDrum captures these phenotypic differences non-invasively in the corresponding rodent models, with NMOSD and MOGAD models documented to produce more severe and less remitting visual deficits than classical MOG35-55 EAE. Also see: Optic Neuritis

The challenge

A key translational problem in the demyelinating disease field is that many preclinical studies use classical MOG35-55 EAE as a generic demyelinating disease proxy, when in fact MS, NMOSD, and MOGAD differ substantially in the immune compartments driving damage. NMOSD is driven primarily by AQP4-specific antibodies that activate complement and recruit granulocytes to attack astrocytes, producing more severe and often bilateral optic neuritis with poor recovery. MOGAD involves MOG-specific IgG that targets the oligodendrocyte surface, producing a more pronounced humoral attack on myelin itself. MS combines T cell-driven inflammation with a substantial B cell and antibody component, particularly in its progressive forms.

This heterogeneity means that a treatment effective in MOG35-55 EAE may not translate to NMOSD or MOGAD. The visual system provides a common functional endpoint across these entities: optic neuritis is a cardinal feature of all three, and OptoDrum-measured visual acuity provides a model-agnostic readout of the severity and recovery of optic nerve injury. However, using the same model for all three diseases conflates their distinct mechanisms and fails to predict treatment response in the clinic.

How Striatech products help

OptoDrum
Measures spatial visual acuity (cycles per degree) and contrast sensitivity via the subcortical optomotor reflex in awake, freely moving rodents. Provides the primary non-invasive functional readout for comparing the severity and recovery trajectory of optic neuritis across MOG35-55 EAE, B cell-dependent EAE, NMOSD passive-transfer, and MOGAD models without anaesthesia or operator bias. Enables repeated measurements across the full disease course in the same animals.
AcuiSee
Measures visual acuity via a cortical operant paradigm requiring learned visual discrimination. Complements OptoDrum by assessing the cortical visual processing dimension of demyelinating disease, which includes the integrity of retino-cortical projections and V1 processing downstream of the optic nerve. Particularly relevant for chronic progressive models where cortical reorganisation or visual plasticity may buffer the OMR response while cortical function remains impaired.
Non-aversive Animal Platform
Reduces handling-stress confounds during functional measurements in EAE animals, which exhibit motor and autonomic dysfunction that can elevate corticosterone and confound visual assessment. Particularly relevant for comparing acuity across disease groups where motor scores differ substantially.

Evidence from the Literature

02
What Shared Mechanisms of T Cell, B Cell, and Antibody-Mediated Injury Operate Across Autoimmune Demyelinating Syndromes, and How Are They Captured with Functional Visual Endpoints?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Despite their entity-specific immunopathology, MS, NMOSD, MOGAD, and ADEM converge on shared downstream effectors: complement activation, RGC death, axon degeneration, and oligodendrocyte loss. Preclinical models spanning T cell-dominant, B cell-dependent, and antibody-transfer designs allow these mechanisms to be dissected individually while using OptoDrum and OCT as shared functional readouts. For the tissue-level consequences of demyelinating axon injury, see Optic Nerve Damage and Axon Degeneration.

The challenge

A critical unresolved question in demyelinating disease research is whether the downstream effectors of axon damage are sufficiently conserved across MS, NMOSD, and MOGAD to justify the same neuroprotective strategies across diseases, or whether disease-specific immune mechanisms produce distinct axonal injury signatures requiring tailored interventions. In MS, the primary T cell wave is followed by secondary oligodendrocyte apoptosis and Wallerian axon degeneration; in NMOSD, complement-driven astrocyte loss leads to a bystander axon injury pattern; in MOGAD, MOG-IgG at the oligodendrocyte surface may trigger a more direct myelin stripping with preserved axon integrity in early stages. Functionally quantifying these differences – and whether they produce different OMR trajectories – is a prerequisite for rational target selection across the disease spectrum.

A particularly important shared mechanism is microglia-mediated myelin processing, whose role has been reframed from uniformly pathological to context-dependent. Groh et al (2023, Nat Commun.) demonstrated that microglial demyelination in the PLP-deficient model is protective, preserving axon integrity and visual function, while Groh et al (2025, Nat Neurosci.) demonstrated that CX3CR1-dependent microglial activation in an aging-autoimmune model drives destructive optic nerve demyelination. This dual biology – protective vs pathological microglial demyelination – is a cross-entity mechanism with direct relevance to therapeutic targeting of microglia in MS, NMOSD, and MOGAD.

How Striatech products help

OptoDrum
Provides a non-invasive functional readout that integrates the cumulative effect of demyelination, axon degeneration, and RGC loss on the retino-brainstem pathway. Enables direct comparison of the functional severity of different immune attack modalities (T cell, B cell, antibody) in the same output metric (cycles per degree), supporting cross-disease mechanistic comparison in the same cohort design.
AcuiSee
Assesses cortical visual function, which may be preserved when subcortical pathways are compromised or vice versa. Adding the AcuiSee cortical endpoint alongside OptoDrum allows dissociation of subcortical and cortical visual pathway vulnerability in demyelinating models.
DarkAdapt
Provides controlled dark-adaptation prior to scotopic OMR testing with the ScotopicKit, enabling assessment of rod-mediated visual pathways. Relevant when demyelinating disease models produce selective rod or cone pathway involvement detectable via scotopic vs photopic OMR comparison.

Evidence from the Literature

03
How Can Visual-Function Endpoints Benchmark Disease-Modifying and Neuroprotective Therapies Across Multiple Autoimmune Demyelinating Models?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

OptoDrum-measured spatial acuity serves as a model-agnostic translational endpoint for evaluating treatment efficacy in EAE, NMOSD, and MOGAD preclinical models. Studies using OptoDrum document preserved visual function after HIF-1 inhibition (metabolic-inflammatory interface), FcRn antibody depletion (immunoglobulin clearance), and histaminergic modulation (neuroimmune communication), spanning mechanistically distinct therapeutic strategies on a single comparable endpoint.

The challenge

Preclinical demyelinating disease therapy benchmarking is hampered by the use of different readouts across studies – motor clinical scoring in EAE, histological axon counts, or electrophysiological VEP – that are difficult to compare across laboratories or disease models and poorly predict clinical visual outcomes. The need for a standardised functional visual endpoint that (1) is non-invasive, (2) can be repeated longitudinally, (3) is quantitative and operator-independent, and (4) integrates the net effect of demyelination and neuroprotection on a visual circuit is acute. OptoDrum fills this role: because the optomotor reflex depends on the integrity of the entire retina-to-brainstem pathway, it captures the integrated consequence of treatment effects at any level from oligodendrocyte survival to axon preservation to RGC survival.

An additional challenge is that different therapeutic strategies target different immune compartments – T cell suppression, B cell depletion, antibody clearance, metabolic rescue, microglial modulation – and the relative contribution of each varies by disease entity. An endpoint that is equally sensitive to all these mechanisms enables their comparison within a unified experimental framework.

How Striatech products help

OptoDrum
Provides the primary functional efficacy endpoint for therapy benchmarking: spatial visual acuity (cycles per degree) measured repeatedly in the same animals throughout the treatment period. Operator-independent and fully automated, supporting blinded efficacy assessment across treatment groups without the subjectivity of clinical motor scoring or histological cell counting.
AcuiSee
Adds a cortical operant acuity endpoint that may detect residual cortical visual function impairment not captured by the subcortical OMR, particularly in chronic progressive models where cortical adaptation could mask the OptoDrum treatment signal.
Non-aversive Animal Platform
Minimises handling stress during repeated functional measurements across treatment groups, reducing corticosterone-driven confounds that may differ between immunosuppressed and control animals.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Anders et al (2023) Front Immunol.
    Demonstrated that pharmacological HIF-1 inhibition reduces optic nerve hypoxia and preserves visual acuity in EAE, using OptoDrum as the primary functional endpoint. Establishes the metabolic-inflammatory interface as a druggable axis for visual neuroprotection in demyelinating disease.
  • Remlinger et al (2022) Neurol. Neuroimmunol. Neuroinflamm.
    Journal Club →
    Validated FcRn blockade (efgartigimod class) as a strategy for reducing circulating MOG-IgG and attenuating antibody-mediated optic neuritis in an EAE/MOGAD model, with OptoDrum documenting visual function preservation as the translational functional endpoint.
  • Morin et al (2021) J. Immunol.
    Feature →
    Used conditional deletion of histidine decarboxylase in specific immune cell populations to demonstrate that histaminergic signalling modulates EAE severity and functional visual outcomes, with OptoDrum confirming that histamine pathway manipulation alters OMR-measured visual acuity. Establishes the histaminergic neuroimmune axis as a pharmacologically accessible target in autoimmune demyelinating disease.
04
How Does Aging Amplify Autoimmune Demyelinating Damage, and What Do Longitudinal Optomotor Trajectories Reveal About the Age-Accelerated Disease Course?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Aging drives two reinforcing mechanisms that amplify demyelinating damage: immunosenescence-driven CD8+ T cell accumulation in CNS white matter and CX3CR1-dependent microglial senescence that shifts microglia from a homeostatic to a pro-inflammatory optic nerve-demyelinating phenotype. Both mechanisms have been quantified with OptoDrum as the longitudinal functional visual endpoint, producing progressive acuity decline superimposed on or accelerating the autoimmune demyelinating injury.

Also see: Systemic Aging and CNS Decline

The challenge

The majority of preclinical MS and autoimmune demyelinating disease research uses young adult animals (8-12 weeks), yet the clinical disease course of MS is substantially modified by aging: secondary progressive MS is age-dependent, older patients have worse recovery from relapses, and primary progressive MS is predominantly a disease of midlife and beyond. The biological mechanisms underlying age-acceleration of demyelinating disease are incompletely understood but implicate immunosenescence (altered T cell repertoire, accumulation of exhausted or cytotoxic CD8+ T cells in white matter), microglial senescence (reduced homeostatic surveillance, amplified CX3CR1-dependent inflammatory activation), and reduced oligodendrocyte precursor cell regenerative capacity.

Functionally capturing the aging-demyelination interaction requires longitudinal endpoints that can be applied repeatedly across months in aging cohorts without the cumulative invasiveness of anaesthesia-dependent methods. OptoDrum meets this requirement: measurements take minutes per animal without sedation, enabling weekly or monthly tracking of visual acuity decline in aging EAE or aging-microglial-activation cohorts alongside younger controls.

How Striatech products help

OptoDrum
Provides repeated, non-invasive spatial visual acuity measurements suitable for months-long aging cohort studies. Documents the progressive acuity decline driven by immunosenescence-associated CD8+ T cell accumulation and age-related CX3CR1-dependent microglial optic nerve demyelination. The subcortical optomotor reflex is robust to normal aging-associated motor slowing, making it a reliable longitudinal endpoint in aged animals.
Non-aversive Animal Platform
Particularly relevant for aged or debilitated animals, who may have difficulty with conventional restraint. The platform-free design minimises stress-response confounds that are disproportionately large in aged animals with dysregulated HPA axes, improving data quality in longitudinal aging-demyelination studies.
AcuiSee
The cortical operant paradigm may detect age-related cortical visual processing decline separately from the subcortical OMR signal, allowing dissociation of aging effects on cortical vs subcortical visual pathways in demyelinating disease cohorts.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Groh et al (2025) Nat Neurosci.
    Journal Club →
    Feature →
    Demonstrated that age-related microglial activation via CX3CR1 drives optic nerve demyelination and RGC death, with OptoDrum documenting the functional visual decline in aged autoimmune animals. Establishes CX3CR1-dependent microglial senescence as a mechanistic amplifier of age-accelerated demyelinating optic nerve injury.
  • Groh et al (2021) Nat. Aging
    Journal Club →
    Demonstrated that CD8+ cytotoxic T cells accumulate progressively in aged CNS white matter and drive axon degeneration, using OptoDrum to track the functional visual consequence longitudinally as a biomarker of immunosenescence-driven neuroinflammation. Provides the foundational evidence for adaptive immune aging as a driver of demyelinating visual pathway decline.
05
How Does Microglial Biology Define the Functional Outcome of Demyelination – Protective Versus Pathological – and What Visual Endpoints Distinguish These Roles Across Autoimmune Demyelinating Models?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Microglia are not uniformly protective or pathological in demyelination: context and signalling state determine whether their myelin-processing activity preserves or destroys axons. OptoDrum has documented both outcomes in directly comparable visual acuity measurements – protective microglial demyelination in PLP-deficient mice maintaining visual function, and CX3CR1-driven pathological demyelination in an aging-autoimmune model producing progressive acuity loss. This dual biology has direct relevance to the translational question of whether microglial-targeting therapies in MS and MOGAD should suppress or modulate microglia.

The challenge

Microglia-targeting is one of the most active therapeutic strategies in CNS demyelinating disease, with agents ranging from CSF1R inhibitors (suppressive) to BTK inhibitors (modulatory) entering clinical development for MS. A central challenge is that preclinical studies have produced contradictory evidence: some show that microglial depletion or suppression worsens remyelination by removing myelin debris; others show that microglial activation drives axon loss and clinical worsening. This contradiction reflects genuine biological context-dependence rather than model artefact.

Groh et al. have published a direct evidence of this duality within the autoimmune demyelinating disease context, using the same functional endpoint (OptoDrum-measured visual acuity) in both a protective and a destructive microglial demyelination scenario.

How Striatech products help

OptoDrum
Provides a shared functional currency for comparing protective and pathological microglial outcomes: visual acuity in cycles per degree, measured non-invasively at matched time points across different demyelinating model systems. Enables direct numerical comparison of functional outcomes between microglial suppression, activation, and context-specific manipulation experiments without confounds from interspecies or inter-assay variability.
AcuiSee
Cortical operant visual acuity provides a complementary endpoint that assesses whether microglial manipulation effects on subcortical visual pathways propagate to cortical processing, relevant when CX3CR1 or CSF1R-dependent microglial states affect higher visual areas beyond the optic nerve.

Evidence from the Literature

Product Fit

Summary: Striatech Products supporting your research questions

Research Question OptoDrum ScotopicKit AcuiSee Photorefractor Keratometer DarkAdapt Non-aversive platform
Cross-disease visual phenotype comparison (MS vs NMOSD vs MOGAD) Yes Yes Yes
Shared T cell / B cell / antibody injury mechanisms Yes Yes Yes Yes
Disease-modifying therapy benchmarking Yes Yes Yes
Aging-demyelination interaction (longitudinal) Yes Yes Yes
Microglial dual-role demyelination context Yes Yes
Notes: ScotopicKit is applicable if rod-pathway visual function is an explicit study endpoint in scotopic EAE or NMOSD protocols. Photorefractor and Keratometer measure refractive state and corneal curvature respectively, and are not relevant to the primarily axonal and retinal endpoints.
Measurement Modalities

Measuring Functional Visual Outcomes in Autoimmune Demyelinating Diseases: How Do Available Methods Compare?

Autoimmune demyelinating disease preclinical research employs a range of visual and neurological readouts. The table below summarises the main modalities, with an emphasis on the dimensions most relevant to cross-disease functional comparison and longitudinal study design.
Modality What It Measures Invasiveness Repeatability in the same animal Cross-model comparability 3Rs relevance
OptoDrum (Striatech) Spatial visual acuity and contrast sensitivity via optomotor reflex (subcortical retina-to-brainstem) Non-invasive; no anaesthesia High; daily or weekly possible High; identical metric across EAE, NMOSD, MOGAD, and aging models Refinement (no restraint, no anaesthesia); enables Reduction by replacing terminal cohorts for functional readouts
AcuiSee (Striatech) Visual acuity via operant forced-choice paradigm (cortical processing required) Non-invasive; food restriction required for motivation High after training phase (10-14 days) High; cortical complement to OptoDrum across models Refinement; provides psychophysical cortical endpoint; no anaesthesia
Visual Evoked Potential (VEP) Cortical response to visual stimulation; latency and amplitude reflect retino-cortical conduction and demyelination severity Invasive; surgical electrode implantation typically required Low to moderate depending on implant Moderate; latency changes specifically sensitive to demyelination; widely used in MS trials as a translational endpoint Lower 3Rs score due to surgical invasiveness; complements OMR for the cortical and conduction dimension
Optical coherence tomography (OCT) Retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL) thickness; structural endpoint only Low to moderate; typically requires anaesthesia or restraint in rodents High High; RNFL thinning is a validated MS biomarker in both clinical and preclinical use Structural endpoint; does not measure functional vision; complements OMR for structure-function correlation
EAE clinical motor scoring Hind-limb paralysis and body weight; reflects spinal cord involvement Non-invasive High Low; scores are not directly comparable across induction protocols or disease entities Moderate; does not capture visual pathway involvement; subjective and scale-dependent
Histological RGC and axon counting RGC soma and optic nerve axon density at a single terminal time point Terminal None Moderate; consistent across models if methodology is standardised Terminal; complements repeated OMR measurements as the structural correlate at study end
Supported by Striatech Products

Publications on Autoimmune Demyelinating Diseases

Keep exploring

Related application areas, neighbouring research chapters, and the questions researchers ask most.

Application Area

Autoimmune Demyelinating Diseases

Multiple sclerosis, NMOSD, MOGAD, and their experimental analogues — distinct immunopathologies that converge on shared cascades of complement activation, microglial myelin stripping, and secondary axon degeneration.

3
Research Chapters
5
FAQs answered
Main Field where Autoimmune Demyelinating Diseases is studied
Neuroinflammation and Autoimmune CNS Disease
Other relevant fields
Ocular Inflammation and Immune-Mediated Eye Disease
Systemic Aging and CNS decline

This page has been generated in part with support of AI. Before publication it has been reviewed by a Striatech editor.

Last updated: 15 July 2026